FdaApplication
NDA 014763
Identifiers
- fda_app_no: NDA014763
Properties
| Property | Value |
|---|---|
| applicant_name | ASTRAZENECA LP |
| application_type | NDA |
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CITANEST | PRILOCAINE HYDROCHLORIDE | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE;INJECTION |
| CITANEST | PRILOCAINE HYDROCHLORIDE | 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE;INJECTION |
| CITANEST | PRILOCAINE HYDROCHLORIDE | 3% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE;INJECTION |
| CITANEST FORTE | EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE | 0.005MG/ML;4% | INJECTABLE;INJECTION |
| CITANEST PLAIN | PRILOCAINE HYDROCHLORIDE | 4% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE;INJECTION |
5 products